[Risk-benefit evaluation of the "micropill" is positive. Results of a multicenter study with Trinovum].
D002986:Clinical Trials as Topic; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D009640:Norethindrone / Q000009:adverse effects*; D012306:Risk
D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; C020416:norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination; D004997:Ethinyl Estradiol; D009640:Norethindrone
Die Nutzen-Risiko-Bilanz der "Mikropille" ist positiv. Ergebnisse einer Multizenter-Studie mit Trinovum.